CL-34 Xenograft Model Service for Colon Cancer

The CL-34 Xenograft Model Service for Colon Cancer provides a robust preclinical platform for evaluating therapeutic efficacy against moderately differentiated colon adenocarcinoma, leveraging a well-characterized human cell line established from a primary right colon tumor. Alfa Cytology delivers comprehensive CL-34 xenograft model construction and pharmacological evaluation services, supporting oncology drug discovery programs with standardized tumor growth monitoring, histopathological analysis, and biomarker assessment to accelerate your preclinical development pipeline.

Overview of CL-34 Xenograft Model for Colon Cancer

The CL-34 cell line, established from a moderately differentiated primary adenocarcinoma of the right colon (TNM stage 2), represents a valuable preclinical model for colon cancer research. This epithelial-like cell line exhibits a near-normal hypodiploid karyotype with characteristic chromosomal instability, making it representative of the chromosomal instability (CIN) phenotype commonly observed in colorectal carcinomas. When implanted into immunodeficient murine hosts, CL-34 cells form subcutaneous or orthotopic xenografts that recapitulate key histopathological features of human colon adenocarcinoma, including glandular architecture and epithelial differentiation patterns. The model has been utilized in multiple studies to evaluate tumor growth kinetics, therapeutic response, and molecular mechanisms underlying colon cancer progression.

Xenograft models derived from CL-34 cells enable researchers to assess drug efficacy in a physiologically relevant context, bridging the translational gap between in vitro findings and clinical applications. Subcutaneous implantation offers rapid tumor establishment with consistent growth rates, while orthotopic transplantation into the cecal wall provides a more natural microenvironment that may better reflect tumor-stromal interactions and metastatic potential. The CL-34 model is particularly suited for evaluating targeted therapies, cytotoxic agents, and combination regimens, with tumor growth inhibition (TGI) serving as a primary efficacy endpoint. Integration of molecular profiling data, including DNA copy number aberrations and protein expression analysis, further enhances the predictive value of this model for preclinical drug development.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting moderately differentiated colon adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through chromosomal instability, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Patient-derived xenograft (PDX) models are created by isolating cancer tissue through a biopsy, culturing it into cell lines, and then transplanting these cell lines into mice. (Boopathy, L, et al., 2025)

Cell Line Information: CL-34

The CL-34 cell line is a well-characterized human colon carcinoma cell line with comprehensive molecular characterization. Its chromosomal instability (CIN) phenotype and near-normal hypodiploid karyotype make it unique among available colon cancer cell lines and essential for preclinical research targeting the most common molecular subtype of colorectal carcinoma.

Our Services

Alfa Cytology offers end-to-end CL-34 Xenograft Model Services tailored to your preclinical research objectives, from cell line expansion and quality control to in vivo tumor establishment, treatment administration, and comprehensive endpoint analysis. Our experienced scientific team ensures rigorous model validation, consistent tumor take rates, and standardized data collection protocols, providing you with reliable, reproducible results to support your oncology drug development decisions. Whether you require subcutaneous or orthotopic implantation, single-agent or combination therapy evaluation, our flexible service platform is designed to accommodate diverse study designs and accelerate your path from discovery to development.

Workflow of CL-34 Xenograft Model Construction

The construction of CL-34 xenograft models follows a standardized, multi-step workflow designed to ensure consistent tumor establishment, reliable growth kinetics, and reproducible therapeutic outcomes. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Expansion and Quality Control: CL-34 cells are expanded from authenticated cryopreserved stocks under standardized culture conditions (DMEM/Ham's F12 with 20% FBS, 37 degrees C, 5% CO2). Cell identity is verified by STR profiling, and mycoplasma contamination is ruled out by PCR prior to inoculation. Cells are harvested at logarithmic growth phase to ensure optimal viability and tumorigenic potential.
2. Recipient Mouse Preparation: Immunodeficient mice (typically NOD-SCID or nude mice, 6-8 weeks old) are acclimatized for one week under controlled environmental conditions. Animals are randomized into treatment groups based on body weight, and baseline measurements are recorded to ensure uniform starting parameters across cohorts.
3. Tumor Cell Inoculation: CL-34 cells are prepared as a cell suspension in serum-free medium mixed with Matrigel (1:1 ratio) to enhance engraftment. For subcutaneous models, 1-5 x 10^6 cells are injected into the flank region. For orthotopic models, cells are surgically implanted into the cecal wall or injected via trans-anal delivery to the distal rectum, depending on study objectives.
4. Tumor Monitoring and Randomization: Tumor growth is monitored by caliper measurement twice weekly, with volume calculated using the formula (length x width^2)/2. Once tumors reach 100-200 mm^3, mice are randomized into vehicle and treatment groups to ensure comparable mean tumor volumes across cohorts before dosing initiation.
5. Treatment Administration: Test compounds are administered according to the predefined dosing regimen (route, frequency, and duration specified in the study protocol). Vehicle controls receive the identical formulation without active compound. Body weight and clinical signs are monitored throughout the treatment period to assess tolerability.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tumor growth inhibition (TGI) is calculated as [(Tumor volume_vehicle - Tumor volume_treatment) / Tumor volume_vehicle] x 100%. Tissue samples are preserved for histopathology (H&E, IHC), biomarker analysis, and molecular profiling as required by the study design.

Figure 2: Schematic workflow illustrating the derivation and construction of the CL-34 Xenograft Model at Alfa Cytology.

Case Study-CL-34 Xenograft Model Development

In a representative preclinical study, Alfa Cytology established CL-34 xenografts in immunodeficient mice to evaluate the efficacy of a novel therapeutic candidate against colon adenocarcinoma. The model demonstrated consistent tumor take rates and predictable growth kinetics, enabling robust statistical comparison between treatment and control cohorts. Tumor growth inhibition data, pharmacokinetic parameters, and biomarker responses were systematically collected to support mechanism-of-action studies and dose-selection decisions. Detailed experimental results and datasets are available upon request---please contact our scientific team to discuss your specific research requirements and access comprehensive study reports tailored to your program needs.

Why Choose Alfa Cytology?

Alfa Cytology provides a scientifically rigorous, client-centered approach to CL-34 xenograft model services, ensuring that every study is designed and executed to meet the highest standards of preclinical research.

• Verified Cell Line Integrity: Validated, authenticated CL-34 cell lines with comprehensive quality control and STR profiling to ensure model integrity.
• High Take Rates and Consistency: Flexible study designs accommodating subcutaneous, orthotopic, and metastatic model configurations tailored to your therapeutic hypothesis.
• Comprehensive Analytical Support: Standardized tumor growth monitoring protocols with twice-weekly caliper measurements and rigorous statistical analysis for reliable TGI calculations.
• Tailored Study Designs: Integrated endpoint analysis including histopathology, immunohistochemistry, and biomarker assessment to support mechanistic insights.
• Standardized Protocols: Experienced scientific team with deep expertise in colon cancer preclinical models, providing consultative support from study design to data interpretation.
• Dedicated Project Management: Streamlined project timelines and transparent communication to accelerate your oncology drug development pipeline.

Contact Us

Ready to advance your colon cancer preclinical research with the CL-34 Xenograft Model? Contact us today to discuss your study objectives, timelines, and customization requirements. Our team is prepared to design a tailored service package that aligns with your drug development goals and delivers actionable, high-quality data. Please reach out to us today via our inquiry form or email to learn more about our CL-34 Xenograft Model services.

For research use only. Not intended for any clinical use.